Drug Profile
BNT 121
Alternative Names: BNT-121; IVAC MUTANOME; Melanoma RNA vaccine personalised - BioNTech/Ribological/TRON; Personalised melanoma vaccine - BioNTech/TRONLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator BioNTech; Ribological; TRON
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease) in Austria (Intralymphatic, Injection)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease) in Germany (Intralymphatic, Injection)
- 01 Apr 2020 BioNTech plans a phase II trial for Non-small cell lung cancer in second half of 2020